Close Menu

NEW YORK – OBI Pharma announced Thursday that the US Food and Drug Administration granted orphan drug designation to its investigational therapy OBI-999 for pancreatic cancer. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.